Currently, healthy animal models play a critical role in the safety evaluation of a drug or health product. However, pharmaceutical companies and regulatory authorities are becoming increasingly interested in the use of animal models of disease (AMD) to better understand the potential risk of a diseased population. Recent publications and recommendations for the use of these models by regulators make the growing interest of the application of AMD highly evident.
StageBio senior pathologist Dr Sherry Morgan recently co-authored an article to highlight recent uses of AMD for nonclinical safety testing. The article, which can be accessed here, provides several examples of safety tests and regulatory filings that show AMD are indeed being used in greater capacity than in years prior.
Download and read “Current use of animal models of disease for nonclinical safety testing” to learn about the applications of AMD, the benefits of doing so, and how pharmaceutical companies and regulatory authorities are using AMD to better understand and respond to potential disease risk.